MikeTrendsTrends right now
AI: reposAPI

search

GLP-1

Trends

  1. 1
    Singapore approves Wegovy for liver disease MASH▼fatGgoogleCA50014 min ago

    Novo Nordisk has received approval in Singapore for Wegovy as the first treatment for MASH, a liver disease involving fibrosis. It marks a new indication for the weight-loss drug beyond obesity and diabetes. Attention centres on how semaglutide could expand into treating fatty liver disease globally.